Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
Summary
This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy. Based on different patterns of disease progression, patients will receive relevant systemic treatments, either with or without local interventional therapy. The primary endpoint is progression-free survival (PFS), while secondary endpoints include overall survival (OS), 1-year OS rate, objective response rate (ORR), disease control rate (DCR), duration of remission (DOR), and safety. Additionally, the study will explore the correlation between patients' clinical pathological characteristics, serum biomarkers, and clinical efficacy.
Timeline
- Start
- 2025-05-22
- Primary completion
- 2027-03-15
- Completion
- 2028-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg | Intravenous |
| Subject | Icaritin | Small molecule | 2.4 g | Oral |
| Subject | Leucovorin | Small molecule | 200 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | 30 mg/kg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 600 mg/m2 | — |